Ranbaxy, Teva settle with New York State

Share this article:

Ranbaxy, Teva and the State of New York settled a dispute that alleges the two generic drugmakers colluded not to challenge each other's right to produce no-name versions of Pfizer's cholesterol-lowering medication Lipitor as well as other medications.

“Agreements between drug manufacturers to protect each other's market positions violate principles of antitrust law, and can lead to higher drug prices,” New York Attorney General Eric Schneiderman said in a statement, as quoted by Bloomberg.

Bloomberg reports that neither company admitted wrongdoing, but the two are forwarding a total of $300,000 to the State of New York to settle the allegations.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.